BARCELONA, 5 DECEMBER (EUROPA PRESS) –
The Bellvitge Institute of Biomedical Research (Idibell) and the Catalan Institute of Oncology (ICO) have identified a new vulnerability to aggressive and metastatic prostate cancer that has become resistant to hormonal treatment. available
Research published in "Nature Communications", and researchers from Columbia University and the University of Berne (Switzerland), open a new therapeutic combination of the type of cancer. Wednesday Idibell and ICO.
The researchers have demonstrated that NSD2 protein levels increase the progression and therapy resistance of tumors, and have experimentally validated these tumors to grow and spread, depending on the protein. , so a therapeutic purpose is being created.
They have used some transgenic apple lines that contain mutations in prostate cancer patients, which only activate in the prostate epithelial cells, as in the majority of patients.
According to these models, when mice developed cancer, the cells from the first prostate tumors and metastasies were isolated and gene expression patterns were studied.
Through bioinformatic tools, researchers have identified genes that are candidates for vulnerability in these aggressive tumors, and in a diversified manner there are factors in malignization and metastasis.
NSD2 is a protein, an enzymatic activity that integrates proteins that provide structural support for the DNA branch.
The changes in the histone generated by the NSD2 actions generate a relaxation of the DNA row compaction level to activate the expression of a gene of a tumorigenic potential.
One of the main assumptions of the researchers who sign this study is that the activation of these genes is due to the resistance to chemotherapeutic treatments that are administered to cancer patients by NSD2. prostate
The researchers work to inhibit the NSD2 function and thus work on molecules that reduce mice that reduce the mammary prostatectomy and make the survival of the experimental model.
The inhibition of this protein can lead to resensitization of prostate tumors by demonstrating resistance against conventional antiandrogen treatment.